Literature DB >> 8100644

Neurochemistry and neuroendocrinology of schizophrenia: a selective review.

J A Lieberman1, A R Koreen.   

Abstract

Neurochemical investigation has played a major role in the search for the cause of schizophrenia. Initial research strategies involved the direct measurement of neurochemical substances in biological fluids. Subsequently, indirect measures of brain biochemistry including pituitary hormones and responses to pharmacologic probes were examined. Recent advances in in vivo functional neuroimaging, biochemical neuropathology, and molecular genetics have extended the scope of clinical neurochemical studies. The historical emphasis on the dopamine neurotransmitter system has subsided in the wake of the demonstrated limitations of the dopamine hypothesis of schizophrenia and increased evidence for the role of other neurotransmitters in the pathophysiology of schizophrenia as well as their interactions with dopamine neural systems. The neurotransmitters that have come under increasing scrutiny include serotonin, norepinephrine, glutamate, and related excitatory amino acids, and the neuropeptides cholecystokinin and neurotensin. In this article, the authors reviewed significant recently published neurochemical and neuroendocrine studies of schizophrenia in the context of previous work and found an extensive but fragmentary body of data which provides neither consistent nor conclusive evidence for any specific etiologic theory. Aspects of the disease and methodological limitations that may account for this as well as future research strategies are discussed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8100644     DOI: 10.1093/schbul/19.2.371

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  16 in total

1.  3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia.

Authors:  Ruth Condray; George G Dougherty; Matcheri S Keshavan; Ravinder D Reddy; Gretchen L Haas; Debra M Montrose; Wayne R Matson; Joseph McEvoy; Rima Kaddurah-Daouk; Jeffrey K Yao
Journal:  Int J Neuropsychopharmacol       Date:  2011-01-28       Impact factor: 5.176

2.  Oxidative stress in schizophrenia: pathogenetic and therapeutic implications.

Authors:  Jeffrey K Yao; Ravinder Reddy
Journal:  Antioxid Redox Signal       Date:  2011-05-04       Impact factor: 8.401

Review 3.  Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view.

Authors:  Jeffrey K Yao; Matcheri S Keshavan
Journal:  Antioxid Redox Signal       Date:  2011-04-21       Impact factor: 8.401

Review 4.  Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications.

Authors:  J K Yao; R D Reddy; D P van Kammen
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

5.  Decreased numerical density of kainate receptor-positive neurons in the orbitofrontal cortex of chronic schizophrenics.

Authors:  L J Garey; K A Von Bussmann; S R Hirsch
Journal:  Exp Brain Res       Date:  2006-02-28       Impact factor: 1.972

6.  Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia.

Authors:  J K Yao; G G Dougherty; R D Reddy; M S Keshavan; D M Montrose; W R Matson; S Rozen; R R Krishnan; J McEvoy; R Kaddurah-Daouk
Journal:  Mol Psychiatry       Date:  2009-04-28       Impact factor: 15.992

Review 7.  Pharmacological manipulations of the alpha 2-noradrenergic system. Effects on cognition.

Authors:  J T Coull
Journal:  Drugs Aging       Date:  1994-08       Impact factor: 3.923

8.  Chronic NT69L potently prevents drug-induced disruption of prepulse inhibition without causing tolerance.

Authors:  Siobhan Briody; Mona Boules; Alfredo Oliveros; Irfan Fauq; Elliott Richelson
Journal:  Behav Brain Res       Date:  2009-10-02       Impact factor: 3.332

Review 9.  Phosphoinositide system-linked serotonin receptor subtypes and their pharmacological properties and clinical correlates.

Authors:  S C Pandey; J M Davis; G N Pandey
Journal:  J Psychiatry Neurosci       Date:  1995-05       Impact factor: 6.186

Review 10.  Markers of vulnerability in schizophrenia.

Authors:  Maria Ladea; Dan Prelipceanu
Journal:  J Med Life       Date:  2009 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.